COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08SPH
|
|||
Drug Name |
Eculizumab
|
|||
Synonyms |
Eculizumab (intravitreal, AMD); Eculizumab (intravitreal, AMD), Alexion; Eculizumab (intravitreal, age-related macular degeneration), Alexion
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Other Indication | Neuromyelitis optica | Approved | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
Company |
Alexion Pharmaceuticals Inc
|
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN complement C5 protein (C5) | Target Info | Inhibitor | [3], [4] |
Inhibition of complement C5 by ravulizumab is a promising treatment for severe COVID19 by reducing the innate immune-mediated consequences of severe coronavirus infection, and can pair well with direct anti-viral therapy. |
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04346797) CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort | |||
2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
3 | Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23. | |||
4 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 125166. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.